Iclaprim

Drug Profile

Iclaprim

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 12 May 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase I Nosocomial infections
  • Suspended Nosocomial pneumonia
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 10 May 2016 Discontinued - Phase-I for Nosocomial infections in European Union (PO)
  • 10 May 2016 Discontinued - Phase-I for Nosocomial infections in USA (PO)
  • 10 May 2016 Discontinued - Phase-II for Skin and soft tissue infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top